M
Milan Lukas
Researcher at Charles University in Prague
Publications - 169
Citations - 12492
Milan Lukas is an academic researcher from Charles University in Prague. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 37, co-authored 139 publications receiving 10901 citations. Previous affiliations of Milan Lukas include First Faculty of Medicine, Charles University in Prague & Academy of Sciences of the Czech Republic.
Papers
More filters
Journal ArticleDOI
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn,Brian G. Feagan,Paul Rutgeerts,Stephen B. Hanauer,Jean-Frederic Colombel,Jean-Frederic Colombel,Bruce E. Sands,Milan Lukas,Richard N. Fedorak,Scott D. Lee,Brian Bressler,I. Fox,Maria Rosario,Serap Sankoh,Jing Xu,Kristin Stephens,Catherine Milch,Asit Parikh +17 more
TL;DR: Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolIZumab (rather than switching to placebo) were morelikely to be in remission at week 52.
Journal ArticleDOI
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
Stephen B. Hanauer,William J. Sandborn,Paul Rutgeerts,Richard N. Fedorak,Milan Lukas,Donald G. MacIntosh,Remo Panaccione,Douglas C. Wolf,Paul F. Pollack +8 more
TL;DR: Adalimumab was superior to placebo for induction of remission in patients with moderate to severe Crohn's disease naive to anti-TNF therapy and was well tolerated.
Journal ArticleDOI
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
Wolfgang Kruis,Fric P,J Pokrotnieks,Milan Lukas,B Fixa,M Kaščák,Michael A. Kamm,J Weismueller,Christoph Beglinger,M Stolte,C Wolff,J Schulze +11 more
TL;DR: The probiotic drug E coli Nissle 1917 shows efficacy and safety in maintaining remission equivalent to the gold standard mesalazine in patients with ulcerative colitis, which underlines the pathogenetic significance of the enteric flora.
Journal ArticleDOI
Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial
William J. Sandborn,Stephen B. Hanauer,Paul Rutgeerts,Richard N. Fedorak,Milan Lukas,Donald G. MacIntosh,Remo Panaccione,Douglas C. Wolf,J. D. Kent,Barry Bittle,Ju Li,Paul F. Pollack +11 more
TL;DR: Adalimumab induced and maintained clinical remission for up to 56 weeks in patients with moderate to severe Crohn’s disease naive to anti-TNF treatment in a follow-on randomised controlled trial.
Journal ArticleDOI
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations
Gert Van Assche,Axel Dignass,Walter Reinisch,C. Janneke van der Woude,Andreas Sturm,Martine De Vos,Mario Guslandi,Bas Oldenburg,Iris Dotan,Philippe Marteau,Alessandro Ardizzone,Daniel C. Baumgart,Geert R. D'Haens,Paolo Gionchetti,Francisco Portela,Boris Vucelić,Johan D. Söderholm,Johanna C. Escher,Sibylle Koletzko,Kaija-Leena Kolho,Milan Lukas,Christian Mottet,Herbert Tilg,Severine Vermeire,F. Carbonnel,Andrew T. Cole,Gottfried Novacek,Max Reinshagen,Epameinondas V. Tsianos,Klaus Herrlinger,Yoram Bouhnik,Ralf Kiesslich,Eduard F. Stange,Simon Travis,James O. Lindsay +34 more
TL;DR: The aim of this Consensus was therefore critically to evaluate the optimal strategies for the management of post-operative recurrence in CD.